Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

Summary

This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

Timeline

Start

2021-05-25

Primary completion

2022-12-27

Completion

2023-01-06

Publications

• Results Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crepy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18.
• Gooderham M, Bunick CG, Yu J, Maslin D, Schneider SKR, Osterdal ML, Sohoel A, Madsen DE, Eichenfield LF. Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial. Dermatol Ther (Heidelb). 2026 Jul;16(7):3275-3283. doi: 10.1007/s13555-026-01767-1. Epub 2026 May 17.
• Bauer A, Guenther L, Woolf R, Didriksen Apol E, Maslin D, Nyholm N, Thoning H, Schuttelaar ML. Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. Contact Dermatitis. 2026 Jul;95(1):91-99. doi: 10.1111/cod.70114. Epub 2026 Mar 3.
• Cohen D, Bewley A, Wollenberg A, Hong HC, Armstrong A, Jonsen E, Maslin D, Thoning H, von Eyben R, Chovatiya R. Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema. Dermatol Ther (Heidelb). 2026 Jan;16(1):423-436. doi: 10.1007/s13555-025-01592-y. Epub 2025 Nov 15.
• Gooderham M, Molin S, Bissonnette R, Worm M, Crepy MN, Stingeni L, Warren RB, Schliemann S, Schuttelaar ML, Ferrucci S, Serra-Baldrich E, Silverberg JI, Balita-Crisostomo CL, Osterdal ML, Plohberger U, Agner T. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025 Jul;93(1):95-103. doi: 10.1016/j.jaad.2025.03.008. Epub 2025 Mar 11.

Drugs

Indications

No indication recorded.